ICU Ed and Todd-Cast
SCCM: PROPHY-VAP and Mailbag
Episode guests
Podcast summary created with Snipd AI
Quick takeaways
- A single dose of Ceftriaxone has shown to significantly reduce the incidence of early ventilator-associated pneumonia (VAP) in patients with acute brain injury, leading to increased ventilator-free days, antibiotic-free days, and lower mortality rates.
- Implementation of a single dose of Ceftriaxone as a preventive measure for early VAP in patients with acute brain injury may improve outcomes, but it is crucial to consider broader implications such as antibiotic stewardship and ecological impact.
Deep dives
Study finds single dose of Ceftriaxone reduces early ventilator-associated pneumonia (VAP)
A recent study published in The Lancet Respiratory Medicine examined the use of a single dose of Ceftriaxone in reducing the incidence of early ventilator-associated pneumonia (VAP) in patients with acute brain injury. The study enrolled patients with a Glasgow Coma Scale (GCS) of 12 or less who were expected to be intubated for at least two days and had a diagnosis of head trauma, stroke, or subarachnoid hemorrhage. The results showed a significant decrease in the incidence of early VAP in the Ceftriaxone group compared to the placebo group. Additionally, the Ceftriaxone group had more ventilator-free days and antibiotic-free days, as well as lower mortality rates, both at 28 days and at 60 days. These findings suggest that a single dose of Ceftriaxone may be an effective strategy for preventing early VAP in patients with acute brain injury.
Remember Everything You Learn from Podcasts
